Key facts
- This page summarizes Dina Katabi's Form 3 filing for Cyclerion Therapeutics, Inc. (CYCN).
- 0 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 11 Dec 2023, 17:09.
Dina Katabi - 30 Nov 2023 Form 3 Insider Report for Cyclerion Therapeutics, Inc. (CYCN)
- Reporting relationship
- Director
- Issuer ticker
- CYCN
- Reported as of
- 30 Nov 2023
- Net transaction value
- $0
- Reporting owner signature
- /s/ Dina Katabi
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Dina Katabi filed Form 3 for Cyclerion Therapeutics, Inc. (CYCN) on 11 Dec 2023.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CYCN
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 20,000
- Date
- 30 Nov 2023
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The Reporting Person was granted 20,000 shares of restricted stock pursuant to the Cyclerion Therapeutics, Inc. 2019 Equity Incentive Plan. 2,500 of these shares vest immediately and the remaining 17,500 shares vest ratably over a 42-month period, provided that the Reporting Person remains as a director of Cyclerion Therapeutics, Inc. on such applicable vesting date, subject to certain exemptions.